Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance ...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the ...

The Fujirebio test offering extends this portfolio to include an FDA-cleared option for use in specialized care settings.

Quest Diagnostics, a leader in diagnostic information services, including advanced diagnostics for brain health, announced it plans to offer laboratory testing based on the Lumipulse G pTau ...

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

The FDA has approved the first blood test for Alzheimer's disease based on a blood test – from Fujirebio – in a step forward for early diagnosis. The test, dubbed the Lumipulse G pTau217/ß ...

The US FDA has authorised a new test that can detect amyloid plaques in early-stage Alzheimer's disease without the use of PET scans, which expose patients to radiation. Fujirebio Diagnostics ...

The Fujirebio test offering extends this portfolio to include an FDA-cleared option for use in specialized care settings. "Our goal is to advance access to quality and innovative blood-based tests for ...